Early experience with remdesivir in SARS-CoV-2 pneumonia.
Identifieur interne : 001674 ( Main/Corpus ); précédent : 001673; suivant : 001675Early experience with remdesivir in SARS-CoV-2 pneumonia.
Auteurs : Emanuele Durante-Mangoni ; Roberto Andini ; Lorenzo Bertolino ; Ferruccio Mele ; Letizia Lucia Florio ; Patrizia Murino ; Antonio Corcione ; Rosa ZampinoSource :
- Infection [ 1439-0973 ] ; 2020.
English descriptors
- KwdEn :
- Adenosine Monophosphate (administration & dosage), Adenosine Monophosphate (adverse effects), Adenosine Monophosphate (analogs & derivatives), Alanine (administration & dosage), Alanine (adverse effects), Alanine (analogs & derivatives), Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Betacoronavirus (drug effects), Betacoronavirus (immunology), COVID-19 (MeSH), Chemical and Drug Induced Liver Injury (diagnosis), Chemical and Drug Induced Liver Injury (etiology), Chemical and Drug Induced Liver Injury (physiopathology), Chemical and Drug Induced Liver Injury (virology), Convalescence (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (virology), Critical Illness (MeSH), Darunavir (administration & dosage), Darunavir (adverse effects), Drug Administration Schedule (MeSH), Drug Combinations (MeSH), Fatal Outcome (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Lopinavir (administration & dosage), Lopinavir (adverse effects), Multiple Organ Failure (chemically induced), Multiple Organ Failure (diagnosis), Multiple Organ Failure (physiopathology), Multiple Organ Failure (virology), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (virology), RNA, Viral (blood), Ritonavir (administration & dosage), Ritonavir (adverse effects), SARS-CoV-2 (MeSH), Torsades de Pointes (chemically induced), Torsades de Pointes (diagnosis), Torsades de Pointes (physiopathology), Torsades de Pointes (virology).
- MESH :
- chemical , administration & dosage : Adenosine Monophosphate, Alanine, Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemical , adverse effects : Adenosine Monophosphate, Alanine, Antiviral Agents, Darunavir, Hydroxychloroquine, Lopinavir, Ritonavir.
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , blood : RNA, Viral.
- chemically induced : Multiple Organ Failure, Torsades de Pointes.
- diagnosis : Chemical and Drug Induced Liver Injury, Multiple Organ Failure, Torsades de Pointes.
- drug effects : Betacoronavirus.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- etiology : Chemical and Drug Induced Liver Injury.
- immunology : Betacoronavirus.
- physiopathology : Chemical and Drug Induced Liver Injury, Multiple Organ Failure, Torsades de Pointes.
- virology : Chemical and Drug Induced Liver Injury, Coronavirus Infections, Multiple Organ Failure, Pneumonia, Viral, Torsades de Pointes.
- COVID-19, Convalescence, Critical Illness, Drug Administration Schedule, Drug Combinations, Fatal Outcome, Humans, Pandemics, SARS-CoV-2.
Abstract
At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.
DOI: 10.1007/s15010-020-01448-x
PubMed: 32418190
PubMed Central: PMC7229436
Links to Exploration step
pubmed:32418190Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early experience with remdesivir in SARS-CoV-2 pneumonia.</title><author><name sortKey="Durante Mangoni, Emanuele" sort="Durante Mangoni, Emanuele" uniqKey="Durante Mangoni E" first="Emanuele" last="Durante-Mangoni">Emanuele Durante-Mangoni</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy. emanuele.durante@unicampania.it.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. emanuele.durante@unicampania.it.</nlm:affiliation></affiliation></author><author><name sortKey="Andini, Roberto" sort="Andini, Roberto" uniqKey="Andini R" first="Roberto" last="Andini">Roberto Andini</name><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bertolino, Lorenzo" sort="Bertolino, Lorenzo" uniqKey="Bertolino L" first="Lorenzo" last="Bertolino">Lorenzo Bertolino</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mele, Ferruccio" sort="Mele, Ferruccio" uniqKey="Mele F" first="Ferruccio" last="Mele">Ferruccio Mele</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Florio, Letizia Lucia" sort="Florio, Letizia Lucia" uniqKey="Florio L" first="Letizia Lucia" last="Florio">Letizia Lucia Florio</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Murino, Patrizia" sort="Murino, Patrizia" uniqKey="Murino P" first="Patrizia" last="Murino">Patrizia Murino</name><affiliation><nlm:affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Corcione, Antonio" sort="Corcione, Antonio" uniqKey="Corcione A" first="Antonio" last="Corcione">Antonio Corcione</name><affiliation><nlm:affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Zampino, Rosa" sort="Zampino, Rosa" uniqKey="Zampino R" first="Rosa" last="Zampino">Rosa Zampino</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32418190</idno><idno type="pmid">32418190</idno><idno type="doi">10.1007/s15010-020-01448-x</idno><idno type="pmc">PMC7229436</idno><idno type="wicri:Area/Main/Corpus">001674</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001674</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early experience with remdesivir in SARS-CoV-2 pneumonia.</title><author><name sortKey="Durante Mangoni, Emanuele" sort="Durante Mangoni, Emanuele" uniqKey="Durante Mangoni E" first="Emanuele" last="Durante-Mangoni">Emanuele Durante-Mangoni</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy. emanuele.durante@unicampania.it.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. emanuele.durante@unicampania.it.</nlm:affiliation></affiliation></author><author><name sortKey="Andini, Roberto" sort="Andini, Roberto" uniqKey="Andini R" first="Roberto" last="Andini">Roberto Andini</name><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bertolino, Lorenzo" sort="Bertolino, Lorenzo" uniqKey="Bertolino L" first="Lorenzo" last="Bertolino">Lorenzo Bertolino</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Mele, Ferruccio" sort="Mele, Ferruccio" uniqKey="Mele F" first="Ferruccio" last="Mele">Ferruccio Mele</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Florio, Letizia Lucia" sort="Florio, Letizia Lucia" uniqKey="Florio L" first="Letizia Lucia" last="Florio">Letizia Lucia Florio</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Murino, Patrizia" sort="Murino, Patrizia" uniqKey="Murino P" first="Patrizia" last="Murino">Patrizia Murino</name><affiliation><nlm:affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Corcione, Antonio" sort="Corcione, Antonio" uniqKey="Corcione A" first="Antonio" last="Corcione">Antonio Corcione</name><affiliation><nlm:affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Zampino, Rosa" sort="Zampino, Rosa" uniqKey="Zampino R" first="Rosa" last="Zampino">Rosa Zampino</name><affiliation><nlm:affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Infection</title><idno type="eISSN">1439-0973</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (administration & dosage)</term><term>Adenosine Monophosphate (adverse effects)</term><term>Adenosine Monophosphate (analogs & derivatives)</term><term>Alanine (administration & dosage)</term><term>Alanine (adverse effects)</term><term>Alanine (analogs & derivatives)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Betacoronavirus (drug effects)</term><term>Betacoronavirus (immunology)</term><term>COVID-19 (MeSH)</term><term>Chemical and Drug Induced Liver Injury (diagnosis)</term><term>Chemical and Drug Induced Liver Injury (etiology)</term><term>Chemical and Drug Induced Liver Injury (physiopathology)</term><term>Chemical and Drug Induced Liver Injury (virology)</term><term>Convalescence (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Critical Illness (MeSH)</term><term>Darunavir (administration & dosage)</term><term>Darunavir (adverse effects)</term><term>Drug Administration Schedule (MeSH)</term><term>Drug Combinations (MeSH)</term><term>Fatal Outcome (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Lopinavir (administration & dosage)</term><term>Lopinavir (adverse effects)</term><term>Multiple Organ Failure (chemically induced)</term><term>Multiple Organ Failure (diagnosis)</term><term>Multiple Organ Failure (physiopathology)</term><term>Multiple Organ Failure (virology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term><term>RNA, Viral (blood)</term><term>Ritonavir (administration & dosage)</term><term>Ritonavir (adverse effects)</term><term>SARS-CoV-2 (MeSH)</term><term>Torsades de Pointes (chemically induced)</term><term>Torsades de Pointes (diagnosis)</term><term>Torsades de Pointes (physiopathology)</term><term>Torsades de Pointes (virology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antiviral Agents</term><term>Darunavir</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term><term>Antiviral Agents</term><term>Darunavir</term><term>Hydroxychloroquine</term><term>Lopinavir</term><term>Ritonavir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term><term>Alanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Multiple Organ Failure</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term><term>Multiple Organ Failure</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term><term>Multiple Organ Failure</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Chemical and Drug Induced Liver Injury</term><term>Coronavirus Infections</term><term>Multiple Organ Failure</term><term>Pneumonia, Viral</term><term>Torsades de Pointes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Convalescence</term><term>Critical Illness</term><term>Drug Administration Schedule</term><term>Drug Combinations</term><term>Fatal Outcome</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32418190</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0973</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Infection</Title><ISOAbbreviation>Infection</ISOAbbreviation></Journal><ArticleTitle>Early experience with remdesivir in SARS-CoV-2 pneumonia.</ArticleTitle><Pagination><MedlinePgn>779-782</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s15010-020-01448-x</ELocationID><Abstract><AbstractText>At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durante-Mangoni</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-5381-3537</Identifier><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy. emanuele.durante@unicampania.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy. emanuele.durante@unicampania.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andini</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertolino</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mele</LastName><ForeName>Ferruccio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Florio</LastName><ForeName>Letizia Lucia</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murino</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcione</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zampino</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Internal Medicine, University of Campania 'L. Vanvitelli', Monaldi Hospital, Piazzale Ettore Ruggieri, 80131, Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Infectious and Transplant Medicine, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Infection</MedlineTA><NlmUniqueID>0365307</NlmUniqueID><ISSNLinking>0300-8126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber><NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance></Chemical><Chemical><RegistryNumber>415SHH325A</RegistryNumber><NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical><Chemical><RegistryNumber>YO603Y8113</RegistryNumber><NameOfSubstance UI="D000069454">Darunavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056486" MajorTopicYN="N">Chemical and Drug Induced Liver Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="N">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069454" MajorTopicYN="N">Darunavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016171" MajorTopicYN="N">Torsades de Pointes</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral therapy</Keyword><Keyword MajorTopicYN="N">COVID 19</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32418190</ArticleId><ArticleId IdType="doi">10.1007/s15010-020-01448-x</ArticleId><ArticleId IdType="pii">10.1007/s15010-020-01448-x</ArticleId><ArticleId IdType="pmc">PMC7229436</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670</Citation><ArticleIdList><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Feb 20;382(8):727-733</Citation><ArticleIdList><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001674 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001674 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32418190
|texte= Early experience with remdesivir in SARS-CoV-2 pneumonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32418190" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |